France Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995

GlobalData’s “France Oncology Market Outlook to 2033” is a comprehensive databook report, covering key market data on the France Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The France Oncology Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for Oncology Market.
• Global corporate-level profiles of key companies operating within the France Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

France Oncology is segmented as follows – _x000D_

• Colorectal Cancer Screening Tests_x000D_

• EGFR Tests_x000D_

• KRAS Tests_x000D_

• HER2 Tests_x000D_

• BRCA Tests_x000D_

• ALK Tests_x000D_

• BRAF Tests_x000D_

• BCR-ABL Tests_x000D_

• PD-L1 Tests

Reasons to Buy

The France Oncology Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 5

2 Introduction 6

2.1 What Is This Report About? 6

2.2 Oncology Market Segmentation 6

2.3 Definitions of Markets Covered in the Report 8

3 Oncology Market, France 15

3.1 Oncology Market, France, Revenue ($m), 2018-2033 15

3.1.1 ALK Tests Market, France, Revenue ($m), by Segment, 2018-2033 18

3.1.2 BCR-ABL Tests Market, France, Revenue ($m), by Segment, 2018-2033 20

3.1.3 BRAF Tests Market, France, Revenue ($m), by Segment, 2018-2033 22

3.1.4 BRCA Tests Market, France, Revenue ($m), by Segment, 2018-2033 24

3.1.5 Colorectal Cancer Screening Tests Market, France, Revenue ($m), by Segment, 2018-2033 26

3.1.6 EGFR Tests Market, France, Revenue ($m), by Segment, 2018-2033 28

3.1.7 HER2 Tests Market, France, Revenue ($m), by Segment, 2018-2033 30

3.1.8 KRAS Tests Market, France, Revenue ($m), by Segment, 2018-2033 32

3.2 Oncology Market, France, Volume (Units), 2018-2033 34

3.2.1 ALK Tests Market, France, Volume (Units), by Segment, 2018-2033 37

3.2.2 BCR-ABL Tests Market, France, Volume (Units), by Segment, 2018-2033 39

3.2.3 BRAF Tests Market, France, Volume (Units), by Segment, 2018-2033 41

3.2.4 BRCA Tests Market, France, Volume (Units), by Segment, 2018-2033 43

3.2.5 Colorectal Cancer Screening Tests Market, France, Volume (Units), by Segment, 2018-2033 45

3.2.6 EGFR Tests Market, France, Volume (Units), by Segment, 2018-2033 48

3.2.7 HER2 Tests Market, France, Volume (Units), by Segment, 2018-2033 50

3.2.8 KRAS Tests Market, France, Volume (Units), by Segment, 2018-2033 52

3.3 Oncology Market, France, Average Price ($) , 2018-2033 54

3.4 Oncology Market, France, Company Share by Revenue ($m), 2024 58

4 Overview of Key Companies in France, Oncology Market 60

4.1 F. Hoffmann-La Roche Ltd 60

4.1.1 Company Overview 60

4.2 Agilent Technologies Inc 60

4.2.1 Company Overview 60

4.3 Abbott Laboratories 60

4.3.1 Company Overview 60

4.4 Qiagen NV 60

4.4.1 Company Overview 60

4.5 Danaher Corp 61

4.5.1 Company Overview 61

4.6 Eiken Chemical Co Ltd 61

4.6.1 Company Overview 61

4.7 Resonac Corporation 61

4.7.1 Company Overview 61

4.8 Alfresa Pharma Corp 61

4.8.1 Company Overview 61

4.9 Hemosure Inc 62

4.9.1 Company Overview 62

4.10 SENTINEL CH SpA 62

4.9.1 Company Overview 62

5 Oncology Market Pipeline Products 63

6 Financial Deals Landscape 128

6.1 Equity Offerings 128

6.1.1 Ikonisys Raises USD0.16 Million in Private Placement of Shares 128

6.1.2 Phaxiam Therapeutics Raises USD8.39 Million in Private Placement of Shares 130

6.2 Partnerships 131

6.2.1 A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix 131

6.3 Private Equity 133

6.3.1 Consortium of Investor to Acquire Eurobio Scientific 133

6.4 Venture Financing 135

6.4.1 HEPTA Medical Raises USD6.29 Million in Series A Financing 135

6.4.2 Spotlight Medical Raises USD6.72 Million in Seed Financing 136

7 Recent Developments 138

7.1 Corporate Communications 138

7.1.1 Feb 11, 2025: UK-backed AI Companies to Transform British Cancer Care and Spark New Drug Breakthroughs 138

7.1.2 Oct 03, 2024: Successful 2024 ISO 13485 Certification Maintenance Strengthening Ikonisys’ Strong Market Position and Growth Potential 139

7.2 Government and Public Interest 140

7.2.1 Apr 14, 2025: Tackling Vulnerabilities in the Supply Chain of Radiopharmaceuticals in the EU 140

7.3 Other Significant Developments 140

7.3.1 Jan 06, 2025: PhenoVista Biosciences Partners with NETRI to Expand Organ-on-Chip Service Offerings for Drug Development 140

7.3.2 Nov 12, 2024: Ikonisys Group Renews Agreement as European Authorized Representative and Importer for Novodiax’s CE IVD-Certified Technology in Oncological Diagnostics and Organ Transplant Safety 141

7.3.3 Oct 31, 2024: CURE51 Chooses 10X Genomics Visium HD for New Drug Discovery Initiative 141

7.3.4 Sep 17, 2024: Precision Microbiome Profiling Demonstrates It Diagnostic Potential in Groundbreaking Work Conducted at Gustave Roussy Cancer Institute 142

7.4 Product News 142

7.4.1 Apr 08, 2025: Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM 142

7.4.2 Jan 20, 2025: Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing From Exploratory Research to Clinical Trials 143

7.4.3 Dec 03, 2024: The Ikonisys Group Unveils its New Vision and Strategy Under the Brand “ALIKO SCIENTIFIC” 143

7.4.4 Nov 21, 2024: Prestigious Cancer Center Institut Curie Introduces Ibex Medical Analytics’ AI Tools for Cancer Diagnostics 144

7.4.5 Aug 26, 2024: Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors 144

7.5 Strategy And Business Planning 145

7.5.1 Feb 26, 2025: OncoHost Announces Collaboration With Gustave Roussy 145

7.5.2 Jan 06, 2025: PhenoVista Biosciences Partners with NETRI to Expand Organ-on-Chip Service Offerings for Drug Development 145

7.5.3 Nov 25, 2024: French Hospital Joins Regional Pathology Solution From Sectra to Enhance Collaboration and Speed Up Cancer Diagnostics 146

7.5.4 Sep 24, 2024: Curium Opens Additional and New Facility in Petten, Netherlands 146

7.5.5 Jun 27, 2024: Spotlight Medical Emerges from Stealth to Tackle the Critical Issue of Inadequate Cancer Treatments 147

8 Appendix 148

8.1 Research Methodology 149

8.1.1 Coverage 149

8.1.2 Secondary Research 149

sssssss8.1.3 Primary Research 149

8.1.4 Market Modeling and Forecasting 150

8.1.5 Company Share Analysis 151

8.1.6 Benchmarking 152

8.2 GlobalData Consulting 153

8.3 Contact Us 153

8.4 Disclaimer 153

Table

Table 1: Oncology Market, France, Revenue ($m), USD Constant, 2018-2033 16

Table 2: ALK Tests Market, France, Revenue ($m), USD Constant, 2018-2033 19

Table 3: BCR-ABL Tests Market, France, Revenue ($m), USD Constant, 2018-2033 21

Table 4: BRAF Tests Market, France, Revenue ($m), USD Constant, 2018-2033 23

Table 5: BRCA Tests Market, France, Revenue ($m), USD Constant, 2018-2033 25

Table 6: Colorectal Cancer Screening Tests Market, France, Revenue ($m), USD Constant, 2018-2033 27

Table 7: EGFR Tests Market, France, Revenue ($m), USD Constant, 2018-2033 29

Table 8: HER2 Tests Market, France, Revenue ($m), USD Constant, 2018-2033 31

Table 9: KRAS Tests Market, France, Revenue ($m), USD Constant, 2018-2033 33

Table 10: Oncology Market, France, Volume (Units), 2018-2033 35

Table 11: ALK Tests Market, France, Volume (Units), 2018-2033 38

Table 12: BCR-ABL Tests Market, France, Volume (Units), 2018-2033 40

Table 13: BRAF Tests Market, France, Volume (Units), 2018-2033 42

Table 14: BRCA Tests Market, France, Volume (Units), 2018-2033 44

Table 15: Colorectal Cancer Screening Tests Market, France, Volume (Units), 2018-2033 46

Table 16: EGFR Tests Market, France, Volume (Units), 2018-2033 49

Table 17: HER2 Tests Market, France, Volume (Units), 2018-2033 51

Table 18: KRAS Tests Market, France, Volume (Units), 2018-2033 53

Table 19: Oncology Market, France, Average Price ($), 2018-2033 54

Table 20: Oncology Market, France, Company Share by Revenue ($m), 2024 59

Table 21: Oncology Market Pipeline Products 63

Table 22: Ikonisys Raises USD0.16 Million in Private Placement of Shares 128

Table 23: Phaxiam Therapeutics Raises USD8.39 Million in Private Placement of Shares 130

Table 24: A. Menarini Diagnostics Enters into Distribution Agreement with Nucleix 131

Table 25: Consortium of Investor to Acquire Eurobio Scientific 133

Table 26: HEPTA Medical Raises USD6.29 Million in Series A Financing 135

Table 27: Spotlight Medical Raises USD6.72 Million in Seed Financing 136

Table 28: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 150

Figures

Figure 1: Oncology Market, France, Revenue ($m), USD Constant, 2018-2033 15

Figure 2: ALK Tests Market, France, Revenue ($m), USD Constant, 2018-2033 18

Figure 3: BCR-ABL Tests Market, France, Revenue ($m), USD Constant, 2018-2033 20

Figure 4: BRAF Tests Market, France, Revenue ($m), USD Constant, 2018-2033 22

Figure 5: BRCA Tests Market, France, Revenue ($m), USD Constant, 2018-2033 24

Figure 6: Colorectal Cancer Screening Tests Market, France, Revenue ($m), USD Constant, 2018-2033 26

Figure 7: EGFR Tests Market, France, Revenue ($m), USD Constant, 2018-2033 28

Figure 8: HER2 Tests Market, France, Revenue ($m), USD Constant, 2018-2033 30

Figure 9: KRAS Tests Market, France, Revenue ($m), USD Constant, 2018-2033 32

Figure 10: Oncology Market, France, Volume (Units), 2018-2033 34

Figure 11: ALK Tests Market, France, Volume (Units), 2018-2033 37

Figure 12: BCR-ABL Tests Market, France, Volume (Units), 2018-2033 39

Figure 13: BRAF Tests Market, France, Volume (Units), 2018-2033 41

Figure 14: BRCA Tests Market, France, Volume (Units), 2018-2033 43

Figure 15: Colorectal Cancer Screening Tests Market, France, Volume (Units), 2018-2033 45

Figure 16: EGFR Tests Market, France, Volume (Units), 2018-2033 48

Figure 17: HER2 Tests Market, France, Volume (Units), 2018-2033 50

Figure 18: KRAS Tests Market, France, Volume (Units), 2018-2033 52

Figure 19: Oncology Market, France, Company Share (%), 2024 58

France Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others standard reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Medical Devices
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Medical Devices
New
AI-designed Materials: Market Trends and Innovations
$995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at France Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others in real time.

  • Access a live France Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.